Chiesi’s Elfabrio receives NICE recommendation
4th September 2023 Uncategorised 0The therapy has been developed for the treatment of Fabry disease among adult patients More: Chiesi’s Elfabrio receives NICE recommendation Source: News
read moreThe therapy has been developed for the treatment of Fabry disease among adult patients More: Chiesi’s Elfabrio receives NICE recommendation Source: News
read moreThe therapy has been developed for the treatment of migraine among adults More: Marketing authorisation for AbbVie’s Aquipta Source: News
read more© 1994 - 2023 B.M. Pharmaceuticals